Actinium Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATNM research report →
Companywww.actiniumpharma.com
Actinium Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.
- CEO
- Sandesh C. Seth
- IPO
- 2012
- Employees
- 31
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $36.71M
- P/E
- -1.56
- P/S
- 407.87
- P/B
- 15.86
- EV/EBITDA
- 0.16
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 538.89%
- Op Margin
- -28346.67%
- Net Margin
- -26078.89%
- ROE
- -218.67%
- ROIC
- -65.71%
Growth & Income
- Revenue
- $90.00K · 0.00%
- Net Income
- $-33,887,000 · 11.39%
- EPS
- $-1.09 · 14.17%
- Op Income
- $-36,247,000
- FCF YoY
- 25.39%
Performance & Tape
- 52W High
- $1.95
- 52W Low
- $0.95
- 50D MA
- $1.18
- 200D MA
- $1.37
- Beta
- -0.11
- Avg Volume
- 175.52K
Get TickerSpark's AI analysis on ATNM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 18, 25 | SETH SANDESH | other | 120,900 |
| Mar 31, 25 | Steinhart Richard I | sell | 72,156 |
| Mar 31, 25 | Steinhart Richard I | sell | 8,333 |
| Mar 31, 25 | Steinhart Richard I | sell | 2,500 |
| Mar 31, 25 | Steinhart Richard I | sell | 2,500 |
| Mar 31, 25 | Steinhart Richard I | sell | 70,311 |
| Mar 31, 25 | Steinhart Richard I | sell | 18,351 |
| Mar 31, 25 | Steinhart Richard I | sell | 8,333 |
| Mar 31, 25 | Steinhart Richard I | sell | 2,500 |
| Mar 31, 25 | Chell Jeffrey W. | sell | 2,500 |
Our ATNM Coverage
We haven't published any research on ATNM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ATNM Report →